CNSP - InvestorNewsBreaks - CNS Pharmaceuticals Inc.(NASDAQ: CNSP) Enters in Purchase Agreements Announces Pricing
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has entered into securities purchase agreements with health-care focused institutional investors. The agreements are for the purchase and sale of 366,000 shares of common stock, or common stock equivalents in lieu thereof, as part of registered direct offering and warrants to purchase up to 366,000 shares of common stock in a concurrent private placement. The shares will be offered at a combined purchase price of $3.75 per share. According to the announcement, the warrants relating to the concurrent private placement will have an exercise price of $3.62 per share and will be immediately exercisable following the date of issuance; the expiration date for the warrants will be five years from the initial exercise date.
The offering is expected to close today, subject to the satisfaction of customary closing conditions, with gross proceeds totaling an estimated $1.37 million, before standard deductions, fees, and expenses. CNS Pharmaceutical anticipates using the funds for working capital and general corporate purposes.
To view the full press release, visit https://ibn.fm/RYsJM
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anticancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information about the company, please visit www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com
InvestorWire is powered by IBN